2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Art. -Nr. Produktname CAS. Nr. Reinheit Chemische Struktur
  • HY-120875
    HX600 172705-89-4 99.40%
    HX600 is a synthetic agonist for RXR (Retinoid X Receptor) heterodimer complex. HX600 prevents ischemia-induced neuronal damage. HX600 has orally bioactivity.
    HX600
  • HY-121539
    Supercinnamaldehyde 70351-51-8 ≥99.0%
    Supercinnamaldehyde is a potent transient receptor potential ankyrin 1 (TRPA1) activator with an EC50 value of 0.8 μM. Supercinnamaldehyde activates TRPA1 ion channels through covalent modification of cysteines.
    Supercinnamaldehyde
  • HY-124751
    YTX-465 2225824-53-1 99.06%
    YTX-465 is a stearoyl-CoA desaturase (Ole1/SCD) inhibitor. YTX-465 inhibits Ole1 and SCD1 with IC50s of 0.039 μM and 30.4 μM, respectively. YTX-465 can be used in the research of Parkinson’s disease and other synucleinopathies.
    YTX-465
  • HY-124866
    PDI-IN-3 922507-80-0 98.0%
    PDI-IN-3 (compound 16F16) is a protein disulfide isomerase (PDI) inhibitor. PDI-IN-3 inhibits cell viability.
    PDI-IN-3
  • HY-124962
    D-NMAPPD 35922-06-6 99.74%
    D-NMAPPD ((1R,2R)-B13) is an acid ceramidase inhibitor. D-NMAPPD regulates NMDA receptor properties by enhancing endogenous production of ceramides. D-NMAPPD has anticancer effecs.
    D-NMAPPD
  • HY-125643
    Pitavastatin lactone 141750-63-2 98.74%
    Pitavastatin lactone is a major metabolite of Pitavastatin (HY-B0144A) in humans. Pitavastatin is a potent competitive inhibitor of HMG-CoA reductase.
    Pitavastatin lactone
  • HY-131879
    NS383 309711-59-9 ≥98.0%
    NS383 is a potent and uniquely selective inhibitor of rat ASICs containing 1a and/or 3 subunits. NS383 inhibits H(+)-activated currents recorded from rat homomeric ASIC1a, ASIC3, and heteromeric ASIC1a+3 with IC50 values ranging from 0.61 to 2.2 μM. NS383 is well tolerated and capable of reversing pathological painlike behaviors, presumably via peripheral actions, but possibly also via actions within central pain circuits.
    NS383
  • HY-135556
    Norfluoxetine 83891-03-6 98.71%
    Norfluoxetine is the active metabolite of antidepressant Fluoxetine (HY-B0102). Norfluoxetine is a selective inhibitor for serotonin uptake.
    Norfluoxetine
  • HY-135761
    Penconazole 66246-88-6 98.91%
    Penconazole is a typical triazole fungicide, and mainly applied on apples, grapes, and vegetables to control powdery mildew. Penconazole inhibits sterol biosynthesis in fungi. Penconazole decrease AChE activity in the cerebrum and cerebellum of rats.
    Penconazole
  • HY-135891
    AZD2423 1229603-37-5 99.91%
    AZD2423 is a potent, selective, orally bioavailable, and non-competitive CCR2 chemokine receptor negative allosteric modulator. AZD2423 has an IC50 of 1.2 nM for CCR2 Ca2+ flux .
    AZD2423
  • HY-136661
    (-)-N6-Phenylisopropyl adenosine 38594-96-6 99.45%
    (-)-N6-phenylisopropyl adenosine (L-Phenylisopropyladenosine) is a selective A1 adenosine receptor agonist. (-)-N6-phenylisopropyl adenosine inhibits K+-induced Ca2+ uptake with an IC50 value of 0.5 µM. (-)-N6-phenylisopropyl adenosine protects against ischemia-induced ventricular arrhythmias and atrial fibrillation, and exacerbates ethanol withdrawal symptoms. (-)-N6-phenylisopropyl adenosine also has analgesic effects.
    (-)-N6-Phenylisopropyl adenosine
  • HY-136706
    Luciferase-IN-1 10205-56-8 98.60%
    Luciferase-IN-1 is a luciferase inhibitor.
    Luciferase-IN-1
  • HY-136975
    Caspase-3-IN-1 872254-32-5
    Caspase-3-IN-1 (compound 11b) is a potent Caspase-3 inhibitor, with an IC50 of 14.5 nM.
    Caspase-3-IN-1
  • HY-13716A
    Noscapine hydrochloride 912-60-7 99.87%
    Noscapine ((S,R)-Noscapine) hydrochloride is an orally active phthalideisoquinoline alkaloid with potent antitussive. Noscapine hydrochloride exerts its antitussive effects by activating sigma opioid receptors and is a non-competitive Bradykinin inhibitor. Noscapine hydrochloride disrupts microtubule dynamics, induces mitotic arrest and apoptosis. Noscapine hydrochloride possesses anticancer, neuroprotective, anti-inflammatory activities, and can crosse the blood-brain barrier.
    Noscapine hydrochloride
  • HY-138119
    γ-Glutamylserine 5875-35-4 99.95%
    γ-Glutamylserine (γ-Glu-Ser) is a calcium receptor activator. γ-Glutamylserine can be used for Parkinson's disease research, as well as diabetes or obesity study.
    γ-Glutamylserine
  • HY-139048
    Fluoroethylnormemantine 1639210-26-6 98.0%
    Fluoroethylnormemantine, a derivative of Memantine, is an antagonist of the N-methyl-D-aspartate (NMDA) receptor. [18F]-Fluoroethylnormemantine can be used as a positron emission tomography (PET) tracer. Fluoroethylnormemantine exhibits anti-amnesic, neuroprotective, antidepressant-like and fear-attenuating effects.
    Fluoroethylnormemantine
  • HY-139667
    PKM2-IN-3 2408841-19-8 99.44%
    PKM2-IN-3 is an inhibitor of PKM2 kinase with an IC50 value of 4.1 μM. PKM2-IN-3 exhibits an anti-neuroinflammatory effect by inhibiting PKM2-mediated glycolysis and NLRP3 activation.
    PKM2-IN-3
  • HY-142042
    3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles 287196-91-2 99.84%
    3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles is an inhibitor for bone morphogenetic protein 2 (BMP2) with an IC50 of 2.2 μM. 3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles is inhibitor for mitogen-activated protein kinase 1 (MEK1). 3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles exhibits anti-inflammatory and neuroprotective activity in EAE mouse model.
    3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles
  • HY-142069
    KB-R7785 168158-16-5 99.90%
    KB-R7785 is a matrix metalloproteinase (MMP) inhibitor, which improves insulin sensitivity by inhibiting TNF-α production. KB-R7785 can be used for diabetes research. KB-R7785 has a protective efficacy against focal cerebral ischemia.
    KB-R7785
  • HY-14405A
    Casopitant mesylate 414910-30-8 99.83%
    Casopitant mesylate (GW679769B) is a potent, selective, brain permeable and orally active neurokinin 1 (NK1) receptor antagonist. Casopitant mesylate is a second in the class of antiemetics that acts to antagonise the emetogenic effect of Substance P (HY-P0201). Casopitant mesylate is also a substrate and a weak-to-moderate inhibitor of CYP3A4. Casopitant mesylate can be used for chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV).
    Casopitant mesylate
Art. -Nr. Produktname / Synonyms Application Reactivity